Further, pCR is a well-recognized predictor of survival benefit in triple-negative and HER2-enriched BC subgroups of patients, whereas in the case of luminal BC subtypes, findings are inconsistent [13, 28, 29]. Here, ERBB2 is linked to breast cancer.